Expand SRPT Menu
SRPT MENU

SRPT Latest Press Releases

-- March 31, 2026 --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:05 PM

-- March 25, 2026 --

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Business Wire 8:05 AM

-- March 24, 2026 --

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Business Wire 4:05 PM

-- March 19, 2026 --

Sarepta Provides Regulatory Update on AMONDYS 45 and VYONDYS 53 Business Wire 8:30 AM

-- March 16, 2026 --

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne Business Wire 8:33 AM

-- February 27, 2026 --

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program Business Wire 9:00 AM

-- February 26, 2026 --

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress Business Wire 8:30 AM

-- February 25, 2026 --

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments Business Wire 4:10 PM

-- February 24, 2026 --

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan Business Wire 9:08 AM

-- February 11, 2026 --

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results Business Wire 8:30 AM

-- February 5, 2026 --

Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL), Sable Offshore Corp. (SOC), Sarepta Therapeutics, Inc. (SRPT), and Semler Scientific, Inc. (SMLR) Globe Newswire 10:47 AM

-- February 4, 2026 --

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease Business Wire 8:30 AM

-- January 26, 2026 --

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients Business Wire 8:00 AM

-- January 23, 2026 --

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy Business Wire 4:05 PM

-- January 12, 2026 --

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues Business Wire 11:58 AM

-- January 7, 2026 --

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease Business Wire 8:30 AM

-- January 5, 2026 --

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire 8:30 AM

-- December 31, 2025 --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:20 PM

-- December 11, 2025 --

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 Business Wire 7:00 AM

-- November 25, 2025 --

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne Business Wire 8:58 AM

-- November 24, 2025 --

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics Business Wire 7:30 AM
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1 Business Wire 7:30 AM

-- November 20, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT PRNewswire 10:00 AM

-- November 14, 2025 --

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information Business Wire 2:54 PM
Market Data Delayed 15 Minutes